Xtant Medical Approves Equity Plan Amendment at Meeting
I'm PortAI, I can summarize articles.
Xtant Medical Holdings approved an amendment to its 2023 Equity Incentive Plan at its annual stockholders meeting on November 7, 2025, increasing shares by 12,300,000. The meeting also included the election of directors and the ratification of Grant Thornton LLP as the accounting firm. Analyst ratings for XTNT stock are currently a Hold with a $1.00 price target, reflecting strong revenue growth but challenges in financial performance. The company specializes in regenerative medicine products, particularly in orthopedics and spine.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments